Last updated: August 28, 2026
Boston Scientific disclosed a cyberattack that has disrupted global ordering and shipping, Tezspire met every endpoint in its Phase 3 eosinophilic esophagitis trial without disclosing a single effect size, and the week’s four open catalyst dates produced zero decisions.
This page covers the Boston Scientific cyberattack and its Stryker precedent, the Tezspire CROSSING results and the growing no numbers disclosure convention, the reported Trump administration pricing deals with midsize biotechs, the FDA’s own Rasonque efficacy data and launch economics, the Generate Biomedicines data leak, and the final tally on the week’s catalyst calendar.
What happened to Boston Scientific?
Boston Scientific identified a cyberattack on Tuesday, August 25 and disclosed it on Wednesday, August 26. The attack disrupted information technology systems and business applications that support order processing and shipping, and the company says the timeline for full restoration is not yet known.
The disruption is global. In its statement, quoted by MedTech Dive, the company said “the full scope, nature and impacts” of the incident “are not yet known,” and it has not determined whether the hit will be material to financial results. The company has not characterized the nature of the attack, and no ransomware claim has been made publicly. Stifel analysts told clients the incident creates “increased uncertainty regarding our 2026 revenue, margin, and earnings per share outlook.”
| Date | Event | BSX close |
|---|---|---|
| Monday, August 24 | Normal operations | $49.01 |
| Tuesday, August 25 | Cyberattack identified internally | $49.86 |
| Wednesday, August 26 | Public disclosure; ordering and shipping disrupted | $48.17 |
| Thursday, August 27 | No restoration timeline given | $46.67 |
Exchange closes; two down sessions took the stock roughly 6.4 percent below its Tuesday close.
Why does the Stryker attack matter as precedent?
Stryker absorbed a cyberattack in March 2026 that disrupted ordering and shipping for weeks and materially hit its first quarter results, per MedTech Dive. That episode gives the market a template for what a device supply attack costs and how long it lingers.
The lesson from March was that a device maker’s commercial engine runs through its order management systems as much as its plants. Hospitals could not place or receive orders, and revenue slid into later quarters or to competitors. Two large cap device makers have now been knocked offline within six months of each other. For hospital systems, the second incident turns dual sourcing of critical devices from a procurement preference into a risk management requirement. For investors, it puts an operational risk line item on every device model that no clinical or regulatory catalyst captures.
What did Tezspire’s CROSSING trial show in eosinophilic esophagitis?
Tezspire met both co primary endpoints at week 24 and every key secondary endpoint through week 52 in CROSSING, a Phase 3 trial of 368 patients with symptomatic, histologically active eosinophilic esophagitis. Amgen and AstraZeneca disclosed no effect sizes and no p values.
The August 27 announcement from Amgen and AstraZeneca confirms the result but reserves the data for an upcoming medical meeting, after which the companies will take the results to regulators.
| CROSSING design element | Detail |
|---|---|
| Population | 368 patients, ages 12 to 80, symptomatic and histologically active eosinophilic esophagitis |
| Arms | 1:1:1 randomization to low dose Tezspire, high dose Tezspire, or placebo, subcutaneous every four weeks |
| Co primary endpoints (week 24) | Histologic remission (peak esophageal eosinophil count of 6 or fewer per high power field) and mean change in the Dysphagia Symptom Questionnaire |
| Key secondaries (week 52) | Sustained histologic remission and symptom improvement, endoscopic disease features (EoE-EREFS), histologic severity and extent (EoE-HSS), endoscopic response and remission measures |
| Result | Both co primaries met; all key secondaries met; no effect sizes disclosed |
| Safety | Consistent with the approved asthma and chronic rhinosinusitis with nasal polyps indications |
Amgen puts the US eosinophilic esophagitis population above 470,000 patients, with prevalence up five fold since 2009 and roughly half of patients inadequately controlled on first line options. Tezspire (tezepelumab), an antibody against thymic stromal lymphopoietin, or TSLP, sits upstream of the inflammatory cascade. Dupixent (dupilumab) has been the only biologic approved in the disease, which makes CROSSING the first Phase 3 challenge to that monopoly from a different mechanism. Regeneron and Sanofi will read the effect sizes at the congress as closely as anyone, because a remission rate in Dupixent’s range from a once monthly injection would set up a genuine share fight.
Why do positive Phase 3 announcements no longer include numbers?
CROSSING is the third positive Phase 3 topline in nine days announced without a single effect size, following Merck and Moderna’s INTerpath-001 on August 19 and Summit and Akeso’s HARMONi-GI1 on August 26. Sponsors are saving the data for medical congresses.
| Announcement | Sponsors | Trial and setting | What was disclosed | What was withheld |
|---|---|---|---|---|
| August 19 | Merck and Moderna | INTerpath-001, resected stage IIB to IV melanoma | Recurrence free survival and distant metastasis free survival met at a prespecified interim | All hazard ratios and event data; congress placement still unannounced |
| August 26 | Summit and Akeso | HARMONi-GI1, first line biliary tract cancer (China) | Overall survival met at an interim; PFS and response secondaries met | All effect sizes |
| August 27 | Amgen and AstraZeneca | CROSSING, eosinophilic esophagitis | Both co primaries and all key secondaries met | All effect sizes and p values |
The convention splits every readout into two tradable events. The topline tells you the trial won; the congress tells you by how much, and the gap between the two can run months. Positions taken on the first event are underwritten on direction alone, and interim analyses tend to flatter the final number. The immediate consequence is that congress placement announcements have quietly become catalyst dates in their own right, and sponsors control them completely.
What did the week’s catalyst calendar actually deliver?
Zero decisions. The week opened with four dated or overdue items on the public calendar, and by Thursday night none had produced a decision. One produced a new date. The only schedule performance came from an exchange controlled tender and an FDA review that finished early.
| Dated item | Status entering the week | What the week produced |
|---|---|---|
| Amylyx $500.2M offering close | Expected “on or about August 21” | Nothing. No closing announcement as of the evening of August 27, six days past the expected date, per the company’s press release index. The underwriters’ 30 day option forces disclosure by roughly September 18 |
| Capricor deramiocel PDUFA | August 22 date passed with no public action | A new date, not a decision: the FDA classified Capricor’s amendment as major and moved the target to November 22 |
| Overton confirmation hearing | Nominated August 19, no hearing date | Still no date as of the evening of August 27 |
| Congressional letter to the FDA on Chinese trial data | Sent around August 20, response pending | Still no public FDA response as of the evening of August 27 |
Two control cases performed. The Arbutus modified Dutch auction opened on schedule on August 24, because exchange listed tender mechanics run on rules rather than discretion. And Rasonque was approved roughly 6.5 months ahead of its FDA goal date, per the agency’s own approval notice, under the Commissioner’s National Priority Voucher pilot, where the agency collects credit for speed. Dates perform when the party controlling them gains from performing. Every remaining date in the fourth quarter roster, including Ultragenyx’s September 19 action date, Scholar Rock’s September 30, Summit’s November 14, Capricor’s November 22, and Vertex’s November 30, is a queue review with no showcase incentive attached.
What are the reported Trump administration pricing deals with midsize biotechs?
Bloomberg reported on August 26 that the White House expects to announce voluntary pricing agreements with midsize biotech companies as soon as Monday. Nothing has been announced yet, and no company has confirmed signing.
Per the Bloomberg report, picked up by Fierce Pharma, the agreements would carry three legs: participating companies would give state Medicaid programs prices aligned with the net prices paid in eight high income countries (Canada, Denmark, France, Germany, Italy, Japan, Switzerland, and the United Kingdom); they would gain exemption from Medicare pilot discount programs now under development; and some may receive tariff relief. State Medicaid participation would be optional. Fierce identified the members of the Midsized Biotech Alliance of America, a coalition formed earlier in 2026 to contest most favored nation pricing policy, as the companies in the frame: Alkermes, Alnylam, BioMarin, Incyte, Madrigal, and Travere. Fourteen large drugmakers have struck versions of these agreements since late 2025. The reported tariff relief leg is worth watching because it converts the Section 232 tariff structure into explicit negotiating currency, which is how this page has read the tariffs since they took effect July 31.
What did the FDA’s Rasonque approval notice add to the record?
The FDA’s own notice confirms the survival medians that had circulated only through wire reporting: median overall survival of 13.2 months versus 6.7 months for standard of care, a 0.40 hazard ratio, and an approval roughly 6.5 months ahead of the agency’s goal date.
| RASolute 302 endpoint (FDA approval notice) | Rasonque | Standard of care | Effect |
|---|---|---|---|
| Median overall survival | 13.2 months | 6.7 months | HR 0.40 (95% CI 0.30 to 0.53), p<0.0001 |
| Median progression free survival | 7.2 months | 3.6 months | HR 0.49, p<0.0001 |
| Overall response rate | 30% | 11% | p<0.0001 |
The notice covers 500 randomized patients and lists Breakthrough Therapy, Orphan Drug, the National Priority Voucher pilot, and Real Time Oncology Review among the pathways used. On the commercial side, Fierce Pharma reports a list price of $39,800 per 30 day supply before discounts, an expanded access program transitioning to commercial supply over several months, a $0 copay support program, and a prescriber base Revolution Medicines splits at roughly 40 percent academic and 60 percent community oncology. Fierce also relays the analyst spread: Evercore ISI models $1.76 billion in 2027 sales while Guggenheim models roughly $900 million in 2027 rising to $2.2 billion by 2028. That is a wide range, and it prices the open question a City of Hope oncologist put plainly to Fierce: this is the company’s first launch.
What leaked from Generate Biomedicines, and why did the stock fall?
Three conference posters covering Phase 1 data on GB-0895, Generate Biomedicines’ AI designed antibody, were inadvertently published on the European Respiratory Society’s website on August 25, roughly two weeks ahead of their September 7 embargo. The company disclosed the leak in an SEC filing.
Per BioSpace’s read of the posters, the 40 patient COPD study showed rapid and sustained reductions across four disease biomarkers after a single dose, a roughly 100 day half life, and anti inflammatory activity lasting at least six months in patients with elevated blood eosinophils; the asthma study showed similar durability at the 300 mg dose. Most adverse events were mild to moderate, with six serious events in five patients, none above Grade 3 and none deemed treatment related. GB-0895 (golukibart) targets TSLP, the same pathway as Tezspire, which makes the coincidence of timing pointed: on the day an approved anti TSLP antibody validated the mechanism in a third disease, the market got an accidental early look at an AI designed challenger with a dosing profile that could stretch to quarterly or better. Generate, a February 2026 IPO from the reopened window, closed at $20.38 on August 25, which BioSpace called an all time high, then fell to $16.14 on August 26 and $15.77 on August 27 as the surprise unwound into scrutiny. The formal ERS presentation remains scheduled for September 7.
Frequently asked questions
Is the Boston Scientific cyberattack ransomware?
Unknown. The company has not characterized the attack type, and no group has been publicly identified. The company statement says the full scope, nature, and impacts are not yet known.
How long could the Boston Scientific disruption last?
The company has given no restoration timeline. The nearest precedent, Stryker’s March 2026 attack, disrupted ordering and shipping for weeks and materially affected quarterly results, per MedTech Dive.
What is Tezspire and how does it work?
Tezspire (tezepelumab) is an antibody from Amgen and AstraZeneca that blocks thymic stromal lymphopoietin, an epithelial cytokine that sits at the top of the inflammatory cascade. It is approved for severe asthma and chronic rhinosinusitis with nasal polyps.
What is eosinophilic esophagitis?
A chronic allergic inflammation of the esophagus marked by eosinophil infiltration, causing difficulty swallowing and food impaction. Amgen cites more than 470,000 diagnosed US patients, a five fold prevalence increase since 2009.
Did Tezspire beat Dupixent in eosinophilic esophagitis?
No comparison exists. CROSSING tested Tezspire against placebo, and no effect sizes have been disclosed. Dupixent remains the only approved biologic in the disease until regulators act on the CROSSING data.
When will the full CROSSING data be available?
Amgen and AstraZeneca say full results will be shared at an upcoming medical meeting and with regulators. No congress has been named.
Why did Amylyx’s offering still not close?
No closing announcement has appeared on the company’s press release index as of the evening of August 27, six days past the expected “on or about August 21” close. The underwriters’ 30 day option expires around September 18, which forces disclosure by then.
What is the new Capricor PDUFA date?
November 22, 2026. The FDA classified Capricor’s submission of 24 month open label extension data as a major amendment and extended the review three months, with the proposed indication refined toward upper limb function.
Why is Capricor’s stock rising without news?
No new company release has appeared since the August 24 extension announcement, per the company’s press release index checked the evening of August 27. The stock has climbed four consecutive sessions, closing at $10.06 on August 27, up roughly 60 percent from its August 21 close of $6.29. We assign no cause.
Which companies would be in the midsize biotech pricing deals?
Per Fierce Pharma, the Midsized Biotech Alliance of America members: Alkermes, Alnylam, BioMarin, Incyte, Madrigal, and Travere. No company has confirmed an agreement, and the White House has announced nothing as of August 27.
What does Rasonque cost?
Fierce Pharma reports a list price of $39,800 per 30 day supply before discounts and rebates, which the company has not published in a press release. Most eligible patients are expected to carry government coverage, per Revolution Medicines’ CFO.
What is GB-0895 (golukibart)?
An anti TSLP antibody designed with Generate Biomedicines’ generative AI platform, in Phase 1 for COPD and asthma, with a roughly 100 day half life per the leaked poster data. Phase 3 asthma planning is underway.
Does the leak change Generate Biomedicines’ timeline?
The ERS presentation remains September 7. The leak moved the disclosure date, not the development plan, though the SEC filing it forced is a reminder that embargo control is an operational risk.
When is the Overton confirmation hearing?
No date has been announced by the Senate HELP Committee as of the evening of August 27. Every FDA decision through at least the fourth quarter is being made by the acting leadership structure.
Sources
Primary sources: Amgen press release on CROSSING Phase 3 results (August 27, 2026); AstraZeneca announcement of the same (August 27, 2026); FDA approval notice for daraxonrasib in metastatic pancreatic adenocarcinoma (posted August 26, 2026); Boston Scientific company statement (August 26, 2026, as quoted by MedTech Dive); Capricor press release on the PDUFA extension (August 24, 2026); Amylyx pricing release (August 19, 2026, Business Wire); Arbutus tender release (August 21, 2026, GlobeNewswire); Generate Biomedicines SEC disclosure (as reported August 27, 2026).
Trade press and market reporting: MedTech Dive and Fierce Biotech on the Boston Scientific cyberattack (August 26 to 27, 2026); Bloomberg News on the midsize biotech pricing agreements (August 26, 2026), via Fierce Pharma (August 27, 2026); Fierce Pharma on the Rasonque launch (August 27, 2026); BioSpace and Endpoints News on the Generate Biomedicines leak (August 27, 2026); BioSpace on Revolution Medicines (August 27, 2026); STAT News Pharmalittle roundup (August 27, 2026). Stock prices are exchange closes.
Related coverage
For the approval that set up this week’s control case, read our breakdown of the Rasonque approval and Biohaven’s $795M epilepsy deal. The empty date framework this week’s tally pays off was set out in our analysis of Capricor’s silent PDUFA date and the Arbutus buyback, and the extension itself in the November 22 PDUFA and narrower label ask. The IPO window Generate Biomedicines came out of is covered in Sentivera’s $1.5B Haisco deal and biotech IPOs near escape velocity, and the week’s binary framework in the binary ledger tally.
